EGF receptor family targets for cancer therapeutics /
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Video |
Language: | English |
Published: |
London :
Henry Stewart Talks,
2007.
|
Series: | Henry Stewart talks. Biomedical & life sciences collection. Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease.
|
Subjects: | |
Online Access: | https://hstalks.com/bs/456/ Series |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Contents: The association of the Epidermal Growth Factor Receptor (EGFR) with the tumorigenic state
- The four related members of the EGFR family (EGFR, erbB2, erbB3 and erbB4)
- Signaling of the activated receptors as either homo- or heteromeric oligomers
- Activation of the EGFR by excess ligand stimulation, receptor over-expression and/or mutation in many carcinomas
- Utility of antibodies and receptor kinase inhibitors which interfere with signaling from the EGFR family as agents in cancer therapy
- The three-dimensional structures for the extracellular domains of EGFR, erbB2, erbB3 and erbB4 and the discovery that EGFR, erbB3 and erbB4 undergo major conformational transitions when interacting with their ligands
- Development of antibodies (mab806) which reduce tumor formation from cells expressing either truncated D2-7 EGFR or over-expressed EGFR by binding to the receptor in a region normally masked by the dimerization of the EGFR extracellular domain
- Use of EGFR antagonists or inhibitors to increase tumor killing by cytotoxic anti-cancer drugs and/or radiation
- Improvement of tumor killing by combining EGFR antagonists and EGFR kinase inhibitors.